Lassa fever: implications of T-cell immunity for vaccine development

Lassa fever is a re-emerging viral hemorrhagic fever, which causes significant human morbidity in endemic regions of West Africa. Attempts to vaccinate against this virus in animal models including non-human primates have revealed that eliciting a strong cellular immune response protects from clinic...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Journal of biotechnology Jg. 73; H. 2; S. 207 - 212
1. Verfasser: ter Meulen, J
Format: Journal Article Tagungsbericht
Sprache:Englisch
Veröffentlicht: Lausanne Elsevier B.V 20.08.1999
Amsterdam Elsevier
New York, NY
Schlagworte:
Animals
Antibodies
Assays
Biological and medical sciences
Biotechnology
Cells
Diseases
Fundamental and applied biological sciences. Psychology
Health. Pharmaceutical industry
Humans
Immunization
Industrial applications and implications. Economical aspects
Lassa Fever - immunology
Lassa Fever - prevention & control
Lassa virus
Lassa virus - immunology
Lymphocyte Activation
Lymphocytic choriomeningitis virus - immunology
Physiological models
Production of active biomolecules
Proteins
T-cell immunity
T-Lymphocytes - immunology
Vaccine development
Vaccins
Viral Vaccines - isolation & purification
Viruses
T-cell immunity
Vaccine development
Lassa virus
Infection
Virus
Human
Lassa fever
Viral disease
Pathogenic
Cellular immunity
Vaccine
Review
Arenaviridae
Arenavirus
ISSN:0168-1656, 1873-4863
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Lassa fever is a re-emerging viral hemorrhagic fever, which causes significant human morbidity in endemic regions of West Africa. Attempts to vaccinate against this virus in animal models including non-human primates have revealed that eliciting a strong cellular immune response protects from clinical disease, but not infection, in the absence of measurable neutralizing antibodies. As there is renewed interest in developing a vaccine against Lassa fever for use in humans, several questions should be addressed in view of the scarce knowledge of the mechanisms of natural immunity against this disease. MHC-dependency of a vaccine relying mainly on the induction of T-cell immunity and its ability to cross-protect against different Lassa virus strains will be important issues. Furthermore, the question whether the vaccine can prevent human-to-human transmission of the virus should be discussed and the possibility that vaccination could predispose to immunopathology should be excluded. We are addressing some of the above mentioned problems concerning natural immunity through field studies in the Republic of Guinea, West Africa, and are presently studying the CD4 cell responses of Lassa antibody positive subjects on the basis of T-cell proliferation assays using recombinant Lassa virus proteins.
Bibliographie:ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-1
ObjectType-Review-3
content type line 23
ObjectType-Article-1
ObjectType-Feature-2
ISSN:0168-1656
1873-4863
DOI:10.1016/S0168-1656(99)00122-4